ACM is down -10.90% during Tuesday's regular session, extending losses after reporting disastrous fiscal Q3 2026 results after Monday's close. The company posted an adjusted loss of -$0.50 per share, badly missing the ~$1.51 consensus estimate, largely due to a $337 million pre-tax charge tied to a delayed construction management project from 2019.

ONON plunged -22.20% during regular trading hours Tuesday after reporting Q2 revenue of CHF 850.3 million, missing the CHF 881.4 million consensus estimate despite beating on EPS (CHF 0.31 vs. CHF 0.29 expected). FY2026 net sales guidance of CHF 3.47–3.56 billion landed at or slightly below consensus, signaling deliberate growth deceleration as the company prioritizes premium brand protection over faster expansion.

Ferrari shares have climbed approximately 8% over the past 30 days, driven by robust Q2 2026 earnings that exceeded expectations and an upward revision to full-year guidance. The company reported Q2 net revenues of €1.94 billion, up 8% year-over-year, with adjusted EBITDA of €755 million and an EBITDA margin of 39%.

Zoom Communications (ZM) surged approximately 19.4% over the last 30 days, climbing from $89.76 on July 10 to $107.20 as of August 10, 2026. The rally was fueled by a powerful combination of strong Q1 FY2027 earnings, raised full-year guidance, and accelerating AI product adoption across the enterprise customer base.

SITM closed at $689.96 during regular trading, falling -4.87% from Friday's close of $725.28, giving back a portion of last week's explosive post-earnings surge. The decline was driven primarily by profit-taking after the stock rallied roughly +33% in the two sessions following its August 5 Q2 earnings beat, where revenue soared +127% YoY to $157.4M and Q3 guidance came in far above consensus.

Tower Semiconductor shares fell approximately 10.5% over the past 30 days, declining from $245.46 on July 1 to $219.67 at the July 31 close. The decline followed a sharp rally triggered by the company's July 14 announcement of a $3 billion Japan expansion plan, after which profit-taking and sector-wide volatility drove shares lower.

Keel Infrastructure (KEEL) shares dropped approximately 27% over the last 30 days, falling from $4.65 on July 10 to $3.40 as of August 10, 2026. The steep decline was triggered by a deeply disappointing Q2 2026 earnings report that revealed a 50% year-over-year revenue decline and a wider-than-expected quarterly loss.

Opendoor Technologies (OPEN) shares declined approximately 27% over the last 30 days, falling from $4.77 to $3.48, driven primarily by a disappointing Q2 2026 earnings report released on August 4. Q2 revenue of $883 million missed analyst estimates of roughly $900 million and plunged 44% year over year, while the net loss widened to $162 million from $29 million a year earlier.

Bollinger Innovations (BINI), formerly Mullen Automotive, trades on OTC Markets after being delisted from Nasdaq in October 2025, with shares priced below $0.10 and a market capitalization of approximately $1 million. The company reported a net loss of $472.94 million on trailing twelve-month revenue of just $9.34 million, reflecting severe operating inefficiencies and negative gross margins exceeding 1,400% in its most recent fiscal year.

Faraday Future Intelligent Electric (FFAI) shares have fallen approximately 84.7% over the last 30 days, dropping from $28.56 on July 10 to $4.37 as of August 10, 2026. A 150:1 reverse stock split, effective July 24, 2026, triggered sharp selling pressure as the company moved to maintain Nasdaq listing compliance.

MicroAlgo Inc. ( MLGO ) currently trades near $4.08, making the $8 target a potential upside of roughly 96% from current levels. The company returned to profitability in fiscal 2025, posting net income of approximately $16.3 million, a 195% year-over-year improvement, alongside an exceptionally low price-to-earnings (P/E) ratio below 2.

Starling Oncology, Inc. recently raised its full-year 2026 revenue guidance to a range of $650 million to $670 million, signaling confidence in operational scaling and contract expansion. Analyst consensus stands at a "Strong Buy" rating with an average price target of approximately $9.00, reflecting optimism around the company's positioning in value-based cancer care.

Ulta Beauty shares surged approximately 17% over the past 30 days, climbing from $469.20 on July 10 to $548.66 on August 10, dramatically outperforming the broader market. The rally reflects a confluence of catalysts: strong first-quarter fiscal 2026 earnings, a raised full-year profit outlook, aggressive share buybacks, and newly disclosed institutional accumulation.

Arxis (ARXS) surged approximately 37.6% over the past 30 days, rallying from $41.79 on July 10 to $57.51 by August 10, driven by a blockbuster second-quarter earnings report. The company reported Q2 2026 revenue of $501 million, up 25% year-over-year, and adjusted EPS of $0.28, soundly beating consensus estimates that had called for a loss of $0.07 per share.

Cognizant Technology Solutions (CTSH) surged approximately 37% over the last 30 days, climbing from $42.57 on July 10 to $58.31 on August 10. The rally was ignited by a strong Q2 2026 earnings report on July 29, featuring better-than-expected revenue, raised full-year EPS guidance, and a $2 billion share buyback authorization.

Regencell Bioscience Holdings (RGC) declined approximately 10.2% over the last 30 days, from $5.88 on July 10 to $5.28 on August 10, 2026. The 30-day slide extends a far steeper quarterly collapse of roughly 81%, with the stock falling from $27.32 in mid-May to current levels near $5.

NIO Inc. (NYSE: NIO) closed at approximately $4.82 on August 10, 2026, meaning a move to $10 would require more than a 100% gain from current levels. The $10 price target sits at the high end of Wall Street analyst estimates — the consensus average is near $7.34, with the most optimistic forecasts reaching $10.04.

ROMA shares gained approximately 12% over the past 30 days, rising from $8.47 to $9.51, propelled by a strategic pivot into AI and high-performance computing infrastructure. Over the last quarter, the stock similarly advanced roughly 12%, though the period included sharp volatility as the company unveiled multiple AI-related initiatives alongside a $200 million at-the-market equity offering program.

Price target in focus: $22 per share, representing the lowest Wall Street analyst target and roughly 75% upside from recent trading levels near $12.59. Strongest bullish catalyst: TONMYA, the first FDA-approved fibromyalgia treatment in over 15 years, posted $11 million in Q2 2026 net sales — nearly tripling quarter-over-quarter — with prescriptions doubling and refills surging 207%.

Bending Spoons (BSP) closed at $51.43 during regular trading, surging +15.70% from the prior session's close of $44.45. The rally was fueled by mounting anticipation ahead of the company's Q2 2026 earnings report, scheduled for release on August 13 before the U.S. market opens.